There is increasing evidence showing that pleiotropy is a widespread phenomenon in complex diseases for which multiple correlated traits are often measured. Joint analysis of multiple traits could increase statistical power by aggregating multiple weak effects.
Introduction
Complex diseases are often characterized by many correlated phenotypes which can better reflect their underlying mechanism. For example, hypertension can be characterized by systolic person's cognitive ability is usually measured by tests in domains including memory, intelligence, language, executive function, and visual-spatial function (Yang and Wang 2012) . Also, more and more large cohort studies have collected or are collecting a broad array of correlated phenotypes to reveal the genetic components of many complex human diseases. Therefore, by jointly analyzing these correlated traits, we can not only gain more power by aggregating multiple weak effects, but can also understand the genetic architecture of the disease of interest (Solovieff et al., 2013) .
Even though genome-wide association studies (GWASs) have been remarkably successful in identifying genetic variants associated with complex traits and diseases, the majority of the identified genetic variants only explain a small fraction of total heritability (Manolio et al., 2009 ). On the other hand, a gene is the basic functional unit of inheritance whereas the GWAS are primarily focused on the paradigm of single common variant. However, most published GWAS only analyzed each individual phenotype separately, although results on related phenotypes may be reported together. Large-scale GWAS of complex traits have consistently demonstrated that, with few exceptions, common variants have moderate-to-small effects.
Thus, it is important to identify appropriate methods that fully utilize information in multivariate phenotypes to detect novel genes in genetic association studies.
In GWAS, several methods have been developed for multivariate phenotypes association analysis (Yang and Wang 2012) to test association between multivariate continuous phenotypes and a single common variant. To our knowledge, current multivariate phenotypes association methods can be roughly classified into two categories: univariate analysis and multivariate analysis. Univariate analysis methods perform an association test for each trait individually and then combines the univariate test statistics or combine the p-values of the univariate tests Multivariate analysis methods jointly analyze more than one phenotype in a unified framework and test for the association between multiple phenotypes and genetic variants. Multivariate analysis methods include multivariate analysis of variance (MANOVA) (Cole et al. 1994 ), linear mixed effect models (LMM) (Laird and Ware 1982) , and generalized estimating equations (GEE) (Liang and Zeger 1986) method. Another special approach is to consider reducing the dimension of the multivariate phenotypes by using dimension reduction techniques. The common method for dimensionality reduction is principal component analysis (PCA) (Ott and Rabinowitz, 1999) which essentially finds the combination of these phenotypes and assumes that the transformed phenotypes are independent. The limitation of this method is that it can not properly account for the variation of phenotypes or genotypes, and also it is hard to interpret the meaning of principle components of the multivariate phenotypes, especially in practice.
Recent studies show that complex diseases are caused by both common and rare variants TOW-CM is based on the score test under a linear model, in which the weighted combination of phenotypes is obtained by maximizing the score test statistic over weights. The weights at which the score test statistic reaches its maximum are called the optimal weights. We also use extensive simulation studies to compare the performance of TOW-CM with MANOVA (Cole et al. 1994) , MSKAT (Wu and Pankow 2016) and minimum p-value (Sha et al., 2012 ). Simulation studies demonstrate that, in all the simulation scenarios, TOW-CM is either the most powerful test or comparable to the most powerful test among the four tests. We also illustrate the usefulness of TOW-CM by analyzing a real whole-genome genotyping data from a COPDGene study.
Methods
We consider a sample with n unrelated individuals. Each individual has K (potentially correlated) traits and has been genotyped at M variants in a considered region (a gene or a pathway).
Denote y ik as the k th trait value of the i th individual and x im as the genotype score in additive coding of the i th individual at the m th variant. Let Y = (Y 1 , · · · , Y K ) denote the random vector of K traits and X = (X 1 , · · · , X M ) denote the random variable of the genotype score at M variants for these n individuals where
We model the relationship between the combination of multiple continuous traits with the M genetic variants in the considered region using linear model
where β 0 is the intercept and β = (β 1 , · · · , β M ) T is the corresponding vector of coefficient. To test the association between the combination of the multiple traits with the M genetic variants is equivalent to test the null hypothesis H 0 : β = 0 under equation (1) . We use the score test statistic given by Sha et al., (2011) to test H 0 : β = 0 under equation (1) . Let P = I n − 1 n 1 n 1 T n and the test statistic is:
where U = (P X) P Y w and V = 1 n (P Y w) P Y w(P X) P X. The score test can be rewritten as a function of w:
where P = P and P P = P . We propose to maximize S(w) to get the optimal weight and then define the statistic to test the effect between the optimally weighted combination of traits with genetic variants.
When D = Y P Y is positive definite, maximizing S(w) is equivalent to maximizing
where L is the lower triangular matrix obtained from the Cholesky decomposition of D = LL T .
However, the matrix of D is usually not full rank because of existing correlation between multiple traits. If the matrix D is semi-positive define matrix, we introduce a ridge parameter λ 0 , for which we suggest the choice λ 0 = 1/n, where n is the number of individuals in the testing data, and modify the adjustment to mitigate the effect of the non-positive matrix D in order to avoid the instability:
and c be the eigenvector corresponding to the largest eigenvalue of the matrix C, then S(w)
is maximized when L w equals to c. Hence equation (4) is maximized when
Specially, if all the traits we consider are independent and M = 1, we can get an analytical weight referred to (Sha et al., 2012) :
for the k th phenotype, k = 1, 2, 3, ..., K. The equation (5) is equivalent to
where the numerator is the correlation coefficient between the k th phenotype Y k and the genotypic variant X and the denominator can be viewed as the variance of the k th phenotype Y k . It means that w k has same direction with the correlation between the phenotype Y k and the genotypic variant X, and puts big weight to the k th trait when it has strong association with the genotypic variant and/or it has low variance.
We define the statistic to test an optimally weighted combination of multiple traits (TOW-
We use permutation methods to evaluate P-values of T . The TOW-CM method can also be extended to incorporate covariates. Suppose that there are p covariates. Let z il denote l th covariate of the i th individual. We adjust both trait value y ik and genotypic score x im for the covariates by applying linear regressions. That is,
Letỹ ik andx im denote the residuals of y ik and x im , respectively. We incorporate the covariate effects in TOW-CM by replacing y ik and x im in equation (6) byỹ ik andx im . With covariates, the statistic of TOW-CM is defined as:
Comparison of tests
We 
Simulation
In simulation studies, we use the empirical Mini-Exome genotype data including genotypes of 697 unrelated individuals on 3205 genes obtained from Genetic Analysis Workshop 17 (GAW17). The genotypes are extracted from the sequence alignment files provided by the 1,000 Genomes
Project for their pilot3 study (http://www.1000genomes.org). To generate the genotype of an individual, we generate two haplotypes according to the haplotype frequencies.
We test K=4 related traits with a compound-symmetry correlation matrix and consider two covariates: a standard normal covariate z 1 and a binary covariate z 2 with P (z 2 = 1) = 0.5. We generate trait values based on genotypes by using the following models: For type I error, phenotypes are generated under the null model i.e. η = 0. To evaluate power, we randomly choose one common variant and n c (20%) rare variants as casual variants.
We assume that all the n c rare causal variants have the same heritability and the heritability of the common causal variant is twice of the heritability of rare causal variants. That is, we model the genotypic variants' contribution to disease risk as η k = β c x c + nc j=1 β kj x j , k = 1, · · · , 4 where x c and x j denote the common variant and rare variant, respectively. β c and β kj represent the corresponding effect size. Let h and h k denote the heritability of all the causal variants for all the K traits and for the k th trait, respectively. We generate K random numbers t 1 , · · · , t K from a uniform distribution between 0 and 1, and the heritability of k th trait denotes
th trait, we assign that the effect size of common variate
and the magnitude of the effect of rare variate
where R denote the ratio of the heritability of rare causal variants to the heritability of the common causal variant. For power comparisons, We conduct simulations for four scenarios:
each time only the first L traits are associated with the rare variant set, L = 1, 2, 3, 4, respectively. Intuitively, in the first scenario (L = 1), when only the first trait is associated with the variants set, the minP method (it equals to test the first trait alone) may have good performance. However, we will show that by simultaneously testing correlated null traits, our proposed method (TOW-CM) could actually improve the detection power compared to test the first trait alone. When there are multiple correlated traits that are associated with the rare variants set, the proposed TOW-CM could offer much improved detection power than the minimum p-value based approach. In each scenario, we also consider different percentage of risk variants for rare variants. In power comparisons, the P-values of TOW-CM, minP are calculated using 1000 permutations, while the P-values of MANOVA and MSKAT are calculated by asymptotic distributions.
Simulation Results
The powers of all the four tests are evaluated using 1000 replicated samples at a significance To evaluate the performance of our proposed method on a real data set, we applied all of the 4 methods (TOW-CM, MANOVA, MSKAT and minP) to the COPD associated genes or genes contain significant single-nucleotide polymorphisms (SNPs) in NHW population with COPD-related phenotypes (Berndt et al. 2012 ). In the analysis, we first removed the missing data in any genotypic variants and then adjusted each of the 7 phenotypes for the 4 covariates using linear models. In the analysis, participants with missing data in any of the 11 variables were excluded. Therefore, a complete set of 5,430 individuals across 50 genes were used in the following analyses. In order to compare these methods, we adopted the commonly used 10 7 permutations for TOW-CM and minP methods. For this verification study, we use 0.05 as significance level for MANOVA, MSKAT and TOW-CM method and use Bonferroni corrected significance level 0.05/7 = 7.14 × 10 −3 for minP methods since this method perform association tests across each trait, respectively. The results are summarized in Table 2 . From Table 2, we can see that TOW-CM identified 14 Genes, minP identified 14 Genes, MANOVA identified (2) there is increasing evidence showing that studying multiple correlated phenotypes jointly may increase power for detecting disease associated genetic variants, and (3) there is a shortage of gene-based approaches for multiple traits. Simulation results show that TOW-CM has correct type I error rates and is consistently more powerful than the other four compared tests.
The real data analysis results show that TOW-CM has excellent performance in identifying genes associated with complex disease with multiple correlated phenotypes such as COPD.
One disadvantage of TOW-CM is that the test statistic does not have an asymptotic distribution and a permutation procedure is needed to estimate its P-value, which is time consuming compared to the methods whose test statistics have asymptotic distributions. To save time when applying TOW-CM to genetic association studies, we can use the step-up procedure (Pan et al. 2014 ) to determine the number of permutations, which can show evidence of association based on a small number of permutations first (e.g. 1,000) and then a large number of permutations are used to test the selected potentially significant genes. Furthermore, TOW-CM method can not only be used for gene-based association studies, but also can be extended to pathway-based analysis or even transcriptome-wide association study (TWAS). How to extend our method to pathway-based analysis or TWAS is our future work. 
